Takeaway
In short, this case enforces the Vaccine Act's protection of a successful claimant's compensation award: counsel cannot bypass the statutory fee cap by relabeling charges as costs, drawing from the claimant's award, or invoking the EAJA.
Amanda Beck received DPT vaccinations at military medical facilities in 1979. After the injections, she developed fever, lethargy, and seizures, and was eventually diagnosed with pertussis encephalopathy causing profound and permanent brain damage. She required lifelong care, medical monitoring, and therapy.
In 1985, Amanda and her father sued the United States under the Federal Tort Claims Act, alleging malpractice in administering the vaccine. They dismissed that action in 1988 to pursue compensation through the newly effective National Vaccine Injury Compensation Program. The Claims Court awarded Amanda $1,276,017 in compensation and awarded her counsel $30,000 for attorney fees and costs.
Counsel then sought additional reimbursement for costs advanced in the Vaccine Act case, approval of an agreement allowing payment from Amanda's compensation award for approximately $34,000 in fees and expenses from the earlier district-court action, fees under the Equal Access to Justice Act, and Rule 11 sanctions. The Claims Court denied each request. Amanda appealed through her counsel.
Issue #1
Whether the Vaccine Act's $30,000 limit on attorney fees and costs permits counsel to recover litigation expenses separately as "advanced costs."
Holding
No. The $30,000 cap covers all litigation charges connected with the Vaccine Act petition, including advanced costs as well as charges for legal services.
Reasoning
Although the statute uses varying terms—"attorneys' fees," "costs," "expenses," and "fee for services"—the court read those provisions together rather than treating each term as a rigidly separate category. Section 300aa-15(e)(1) pairs attorney fees with other costs, while section 300aa-15(e)(2) describes attorneys' time as part of costs and expenses. That shifting usage made counsel's proposed fee-versus-cost distinction untenable.
Section 300aa-15(e)(3) bars an attorney from charging a client any additional "fee for services" beyond the amount awarded under the Act. In context, that prohibition protects the claimant's recovery from all additional litigation charges, not merely hourly legal fees relabeled as such.
The legislative history reinforced this reading. Congress designed the Vaccine Program as a relatively prompt, economical, no-fault alternative to tort litigation and expected legal expenses to remain well below the statutory ceiling. Allowing attorneys to recover additional expenses from clients would frustrate Congress's effort to provide compensation while keeping the Program's legal costs limited.
Counsel's concerns that the cap was inadequate and might create conflicts between lawyer and client were policy arguments for Congress, not grounds for the court to revise the enacted statutory limit.
Issue #2
Whether counsel may be paid, from Amanda's Vaccine Act compensation award, for fees and expenses incurred in the earlier district-court tort action.
Holding
No. Compensation awarded to a vaccine-injured claimant may not be used to pay counsel's fees or costs from the prior civil action.
Reasoning
The court distinguished between an attorney's possible ability to seek payment for work in the prior civil suit and the narrower question presented: whether those charges could be paid from Amanda's Vaccine Act award. Section 300aa-15(e)(3) did not automatically erase all fee agreements relating to the earlier litigation, but that did not authorize payment from the compensation fund.
Amanda's award was calculated to meet her particular medical, rehabilitative, custodial, and other injury-related needs over her expected lifetime. The court rejected the argument that a relatively small attorney payment would leave Amanda unharmed; if the award had excess funds, that would mean the compensation calculation was too high, not that the surplus belonged to her lawyer.
The Act separately provides for attorney compensation and specifies that a claimant's award cannot be used for anything other than the health, education, or welfare of the vaccine-injured person. Paying counsel for earlier litigation would reduce funds Congress designated for Amanda's needs and would not qualify as spending for her health, education, or welfare.
Issue #3
Whether the Claims Court had jurisdiction to disapprove the fee agreement while the Vaccine Act case was before it.
Holding
Yes. While the case was pending, the Claims Court could disapprove the agreement because it conflicted with the statutory allocation of claimant compensation and attorney payment.
Reasoning
The Claims Court, an Article I court, had only the authority Congress granted it and lacked general equitable power to issue injunctions. The Vaccine Act's authorization to issue orders assuring prompt payment of compensation did not broadly authorize ongoing supervision of how compensation would later be spent.
Still, the court necessarily had authority to adjudicate the petition before it and to specify the proper allocation of the award between the claimant and counsel. Disapproving an agreement that would divert protected compensation to counsel was part of carrying out that adjudicative responsibility, not an impermissible advisory opinion.
The Federal Circuit limited its ruling to the agreement before the Claims Court during the pending case. It did not decide whether the Claims Court would retain authority to enjoin a later agreement after the case ended; that question could implicate state probate courts or other state or federal courts.
Issue #4
Whether the Equal Access to Justice Act may supplement the Vaccine Act fee award and permit recovery beyond the $30,000 cap.
Holding
No. The EAJA cannot be used to evade the Vaccine Act's specific and comprehensive limitation on attorney-fee recovery.
Reasoning
The EAJA applies except where another statute specifically provides otherwise. The Vaccine Act specifically provides for attorney fees whenever compensation is awarded, but limits the amount available in retrospective cases to $30,000.
The court's earlier decision in Gavette allowed EAJA fees to supplement another fee statute only where the other statute covered a narrower set of circumstances or imposed a more demanding standard for fees. That principle did not apply here because the Vaccine Act's entitlement standard was more generous than the EAJA's, while its limit was monetary.
Counsel was not seeking EAJA fees because the Vaccine Act failed to cover a category of eligible cases. He sought them to overcome Congress's express cap on the total recovery. The EAJA could not be used for that purpose.
Issue #5
Whether the Claims Court abused its discretion by declining to impose Rule 11 sanctions and award attorney fees against the government.
Holding
No. Counsel identified no signed pleading, motion, or other paper that violated Rule 11.
Reasoning
Rule 11 addresses a specific abuse: the signing of a paper that lacks factual or legal grounding or is filed for an improper purpose. Counsel's allegations instead amounted to a general complaint about the government's litigation conduct, which did not identify a sanctionable signed filing.
Because no prima facie Rule 11 violation was shown, the Claims Court did not abuse its discretion in denying sanctions. The Federal Circuit therefore had no need to resolve whether sovereign immunity would bar such sanctions against the government or whether Rule 11 applied in Vaccine Act proceedings before a special master.